IE43573B1 - Protein having thymus hormone-like activity - Google Patents

Protein having thymus hormone-like activity

Info

Publication number: IE43573B1
Authority: IE; Ireland
Prior art keywords: fraction; molecular weight; cohn; human; prealbumin
Prior art date: 1975-03-24

Application number

IE61676A

Other languages

English (en)

Other versions

IE43573L (en

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1975-03-24

Filing date

1976-03-23

Publication date

1981-04-08

1976-02-17 Priority claimed from US05/658,200 external-priority patent/US4046877A/en

1976-03-23 Application filed by Syntex Inc filed Critical Syntex Inc

1976-09-24 Publication of IE43573L publication Critical patent/IE43573L/xx

1981-04-08 Publication of IE43573B1 publication Critical patent/IE43573B1/en

Links

210000001541 thymus gland Anatomy 0.000 title claims description 14
230000003054 hormonal effect Effects 0.000 title claims description 9
102000004169 proteins and genes Human genes 0.000 title description 16
108090000623 proteins and genes Proteins 0.000 title description 16
239000000463 material Substances 0.000 claims abstract description 66
230000001900 immune effect Effects 0.000 claims abstract description 28
210000002966 serum Anatomy 0.000 claims abstract description 23
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims abstract description 22
229910052921 ammonium sulfate Inorganic materials 0.000 claims abstract description 22
235000011130 ammonium sulphate Nutrition 0.000 claims abstract description 22
108010071690 Prealbumin Proteins 0.000 claims abstract description 18
102000007584 Prealbumin Human genes 0.000 claims abstract description 18
238000004587 chromatography analysis Methods 0.000 claims abstract description 15
210000004369 blood Anatomy 0.000 claims abstract description 14
239000008280 blood Substances 0.000 claims abstract description 14
230000001472 cytotoxic effect Effects 0.000 claims abstract description 14
239000012535 impurity Substances 0.000 claims abstract description 14
229920001282 polysaccharide Polymers 0.000 claims abstract description 14
239000005017 polysaccharide Substances 0.000 claims abstract description 14
238000001914 filtration Methods 0.000 claims abstract description 13
238000005194 fractionation Methods 0.000 claims abstract description 11
150000004676 glycans Chemical class 0.000 claims abstract description 11
231100000433 cytotoxic Toxicity 0.000 claims abstract description 10
239000012510 hollow fiber Substances 0.000 claims abstract description 6
239000002904 solvent Substances 0.000 claims abstract description 6
231100000252 nontoxic Toxicity 0.000 claims abstract description 5
230000003000 nontoxic effect Effects 0.000 claims abstract description 5
239000003186 pharmaceutical solution Substances 0.000 claims abstract description 3
238000000034 method Methods 0.000 claims description 64
238000002360 preparation method Methods 0.000 claims description 52
230000015572 biosynthetic process Effects 0.000 claims description 14
239000000243 solution Substances 0.000 claims description 14
238000007792 addition Methods 0.000 claims description 12
239000002244 precipitate Substances 0.000 claims description 12
239000012149 elution buffer Substances 0.000 claims description 9
238000001502 gel electrophoresis Methods 0.000 claims description 9
239000006228 supernatant Substances 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 7
238000001997 free-flow electrophoresis Methods 0.000 claims description 6
229920002401 polyacrylamide Polymers 0.000 claims description 6
229920002307 Dextran Polymers 0.000 claims description 5
102000009027 Albumins Human genes 0.000 claims description 4
108010088751 Albumins Proteins 0.000 claims description 4
238000011026 diafiltration Methods 0.000 claims description 4
238000000502 dialysis Methods 0.000 claims description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
239000012062 aqueous buffer Substances 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 9
239000001166 ammonium sulphate Substances 0.000 abstract 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 70
210000004698 lymphocyte Anatomy 0.000 description 54
101000772194 Homo sapiens Transthyretin Proteins 0.000 description 49
239000005556 hormone Substances 0.000 description 42
229940088597 hormone Drugs 0.000 description 42
241000699670 Mus sp. Species 0.000 description 38
238000003556 assay Methods 0.000 description 34
230000000694 effects Effects 0.000 description 31
238000000338 in vitro Methods 0.000 description 31
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
210000004989 spleen cell Anatomy 0.000 description 21
108091003079 Bovine Serum Albumin Proteins 0.000 description 20
229940098773 bovine serum albumin Drugs 0.000 description 19
238000000746 purification Methods 0.000 description 17
235000018102 proteins Nutrition 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 13
210000000952 spleen Anatomy 0.000 description 13
239000000872 buffer Substances 0.000 description 12
206010070834 Sensitisation Diseases 0.000 description 11
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
229960002170 azathioprine Drugs 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
210000001165 lymph node Anatomy 0.000 description 10
229920005654 Sephadex Polymers 0.000 description 9
239000012507 Sephadex™ Substances 0.000 description 9
210000003743 erythrocyte Anatomy 0.000 description 9
230000002269 spontaneous effect Effects 0.000 description 9
238000003786 synthesis reaction Methods 0.000 description 9
241001494479 Pecora Species 0.000 description 8
239000000499 gel Substances 0.000 description 8
230000035800 maturation Effects 0.000 description 8
230000008313 sensitization Effects 0.000 description 8
238000004166 bioassay Methods 0.000 description 7
239000012153 distilled water Substances 0.000 description 7
239000012528 membrane Substances 0.000 description 7
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
208000017604 Hodgkin disease Diseases 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
230000001747 exhibiting effect Effects 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
238000011580 nude mouse model Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
239000004471 Glycine Substances 0.000 description 5
238000005227 gel permeation chromatography Methods 0.000 description 5
230000036039 immunity Effects 0.000 description 5
210000003563 lymphoid tissue Anatomy 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
239000000725 suspension Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000699660 Mus musculus Species 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
230000024932 T cell mediated immunity Effects 0.000 description 4
102000007501 Thymosin Human genes 0.000 description 4
108010046075 Thymosin Proteins 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
239000008367 deionised water Substances 0.000 description 4
229910021641 deionized water Inorganic materials 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000004108 freeze drying Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000002243 precursor Substances 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
WISNYKIQFMKSDQ-UHFFFAOYSA-N sodium;6-(3-methyl-5-nitroimidazol-4-yl)sulfanylpurin-9-ide Chemical compound [Na+].CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1[N-]C=N2 WISNYKIQFMKSDQ-UHFFFAOYSA-N 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 3
208000000398 DiGeorge Syndrome Diseases 0.000 description 3
208000010747 Hodgkins lymphoma Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
208000002715 Thymic aplasia Diseases 0.000 description 3
230000005875 antibody response Effects 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
239000011651 chromium Substances 0.000 description 3
230000002354 daily effect Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
239000012465 retentate Substances 0.000 description 3
238000012552 review Methods 0.000 description 3
239000013049 sediment Substances 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
241000894007 species Species 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
201000005990 thymic dysplasia Diseases 0.000 description 3
230000002992 thymic effect Effects 0.000 description 3
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
201000008808 Fibrosarcoma Diseases 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000035584 blastogenesis Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
229960003067 cystine Drugs 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
239000003480 eluent Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000012847 fine chemical Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000001155 isoelectric focusing Methods 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
210000005210 lymphoid organ Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
230000001235 sensitizing effect Effects 0.000 description 2
210000001626 skin fibroblast Anatomy 0.000 description 2
BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000000724 thymus hormone Substances 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
239000004474 valine Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241001245789 Goodea atripinnis Species 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000396922 Pontia daplidice Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
238000010266 Sephadex chromatography Methods 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000011149 active material Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
150000001844 chromium Chemical class 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003372 endocrine gland Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229940073062 imuran Drugs 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
JABGXPCRNXUENL-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1N=CNC2=NC=N[C]12 JABGXPCRNXUENL-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000008747 mitogenic response Effects 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
238000000424 optical density measurement Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
238000001814 protein method Methods 0.000 description 1
230000036647 reaction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
208000005057 thyrotoxicosis Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

IE61676A 1975-03-24 1976-03-23 Protein having thymus hormone-like activity IE43573B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US56140975A	1975-03-24	1975-03-24
US59711675A	1975-07-18	1975-07-18
US05/658,200 US4046877A (en)	1975-07-18	1976-02-17	Method of increasing immunologic competence

Publications (2)

Publication Number	Publication Date
IE43573L IE43573L (en)	1976-09-24
IE43573B1 true IE43573B1 (en)	1981-04-08

Family

ID=27415851

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE61676A IE43573B1 (en)	1975-03-24	1976-03-23	Protein having thymus hormone-like activity

Country Status (11)

Country	Link
JP (1)	JPS51118822A (2)
AU (1)	AU509024B2 (2)
CA (1)	CA1056305A (2)
DE (1)	DE2612015A1 (2)
ES (1)	ES446334A1 (2)
FR (1)	FR2305191A1 (2)
GB (1)	GB1511602A (2)
IE (1)	IE43573B1 (2)
NL (1)	NL7603020A (2)
NZ (1)	NZ180367A (2)
SE (1)	SE7603556L (2)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4818763A (en) *	1984-01-12	1989-04-04	Volker Rusch	Biologically active substance with hormonal properties, production process thereof and utilization of histones for medical purposes
RU2121843C1 (ru) *	1992-12-01	1998-11-20	Старцев Виктор Федорович	Способ получения иммунокорригирующего препарата из крови млекопитающих
RU2164142C1 (ru) *	2000-02-15	2001-03-20	Евгений Михайлович Шутаев	Способ получения биологически активного средства для нормализации физиологического состояния

1976
- 1976-03-18 CA CA248,173A patent/CA1056305A/en not_active Expired
- 1976-03-18 GB GB1100976A patent/GB1511602A/en not_active Expired
- 1976-03-20 DE DE19762612015 patent/DE2612015A1/de not_active Withdrawn
- 1976-03-22 NZ NZ18036776A patent/NZ180367A/xx unknown
- 1976-03-23 NL NL7603020A patent/NL7603020A/xx not_active Application Discontinuation
- 1976-03-23 SE SE7603556A patent/SE7603556L/ not_active Application Discontinuation
- 1976-03-23 IE IE61676A patent/IE43573B1/en unknown
- 1976-03-23 JP JP51031883A patent/JPS51118822A/ja active Pending
- 1976-03-23 FR FR7608401A patent/FR2305191A1/fr active Granted
- 1976-03-24 ES ES446334A patent/ES446334A1/es not_active Expired
- 1976-03-24 AU AU12308/76A patent/AU509024B2/en not_active Expired

Also Published As

Publication number	Publication date
NZ180367A (en)	1978-07-28
SE7603556L (sv)	1976-10-22
AU1230876A (en)	1977-09-29
ES446334A1 (es)	1977-12-16
JPS51118822A (en)	1976-10-19
DE2612015A1 (de)	1976-10-14
NL7603020A (nl)	1976-09-28
AU509024B2 (en)	1980-04-17
IE43573L (en)	1976-09-24
GB1511602A (en)	1978-05-24
CA1056305A (en)	1979-06-12
FR2305191B1 (2)	1978-11-17
FR2305191A1 (fr)	1976-10-22

Publication	Publication Date	Title
Mannick et al.	1967	Prolongation of allograft survival by an alpha globulin isolated from normal blood
Fawcett et al.	1968	Biosynthesis and release of neurophysin
Trainin	1974	Thymic hormones and the immune response.
US4571336A (en)	1986-02-18	Immune stimulation
US4481137A (en)	1984-11-06	Glycoproteins and processes for their production
Barba et al.	1983	Lung injury mediated by antibodies to endothelium. I. In the rabbit a repeated interaction of heterologous anti-angiotensin-converting enzyme antibodies with alveolar endothelium results in resistance to immune injury through antigenic modulation.
US4250084A (en)	1981-02-10	Purified thymic hormone (THF), its preparation and pharmaceutical compositions containing it
JPH07505609A (ja)	1995-06-22	Ｃｄ８結合ドメイン・ペプチド
US4444757A (en)	1984-04-24	Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
Valdimarsson et al.	1974	Restoration of T-lymphocyte deficiency with dialysable leucocyte extract
US4046877A (en)	1977-09-06	Method of increasing immunologic competence
Ardeman et al.	1965	Studies on Human Gastric Intrinsic Factor OBSERVATIONS ON ITS POSSIBLE ABSORPTION AND ENTEROHEPATIC CIRCULATION
JPH0723398B2 (ja)	1995-03-15	初乳由来ポリペプチド因子
IE43573B1 (en)	1981-04-08	Protein having thymus hormone-like activity
JPS6236325A (ja)	1987-02-17	リユ−マチ性関節炎のような自已免疫疾患の抑制因子による治療
EP0254647A2 (en)	1988-01-27	Medicines for treatment of autoimmune diseases
EP0722735A1 (en)	1996-07-24	Parathyroid hypertensive factor
JP2954248B2 (ja)	1999-09-27	ナトリウム排泄増加ホルモン
Rumjanek et al.	1978	Cell-mediated immunological responsiveness in mice decomplemented with cobra venom factor
Górski et al.	1979	Circulating suppressor cells in aplastic anemia
AU692931B2 (en)	1998-06-18	Cell growth regulator
CA2078805C (en)	1997-02-25	Cytokine preparation
Rabinowitz et al.	1980	Aorta contains extractable immunosuppressant activity
Ghanta et al.	1991	Effect of thymic hormone treatment on several immune functions of nude mice
EP0122926A1 (en)	1984-10-31	Immune stimulator